Latest Updates

Strong bipartisan support from the powerful Senate Finance Committee indicates that DIR fee reform remains a priority issue in the ongoing drug pricing debate.

The National Community Pharmacists Association (NCPA) recently issued a call to action to urge pharmacists to ask U.S. Senators on the Senate Finance Committee to sign onto a bipartisan letter addressed to HHS and CMS asking the Administration to revive DIR fee reform for plan year 2021. Take action immediately and urge your Senator to join their committee colleagues as a signatory on this letter.